Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (7): 578-582    DOI: 10.19485/j.cnki.issn2096-5087.2023.07.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
2012—2021年台州市新报告HIV/AIDS病例首次CD4+T淋巴细胞检测结果分析
王婷婷1, 汪剡灵1, 李桂霞2, 常玥2
1.台州市疾病预防控制中心艾滋病性病防制科,浙江 台州 318000;
2.台州市疾病预防控制中心,浙江 台州 318000
Analysis of the first measurement of CD4+T lymphocyte cell counts of newly reported HIV/AIDS cases in Taizhou City from 2012 to 2021
WANG Tingting1, WANG Shanling1, LI Guixia2, CHANG Yue2
1. Department of AIDS and STDS Control and Prevention, Taizhou Center for Disease Control and Prevention, Taizhou, Zhejiang 318000, China;
2. Taizhou Center for Disease Control and Prevention, Taizhou, Zhejiang 318000, China
全文: PDF(878 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2012—2021年浙江省台州市新报告艾滋病病毒感染者和艾滋病患者(HIV/AIDS)首次检测CD4+T淋巴细胞(CD4细胞)水平和检测及时性,为加强HIV/AIDS病例随访管理提供依据。方法 通过中国疾病预防控制信息系统艾滋病综合防治信息系统收集2012—2021年台州市新报告HIV/AIDS病例资料,主要包括人口学信息和CD4细胞首次检测结果,分析HIV/AIDS病例首次检测CD4细胞计数、检测时间分布及其变化趋势。采用多因素logistic回归模型分析首次检测CD4细胞计数的影响因素。结果 2012—2021年台州市新报告HIV/AIDS病例4 834例,其中男性3 889例,占80.45%;20~<40岁2 005例,占41.48%;农民2 130例,占44.06%。首次检测CD4细胞<200个/mm3 1 664例,占34.42%;200~499个/mm3 2 576例,占53.29%;≥500个/mm3 594例,占12.29%。2012—2021年CD4细胞计数<200个/mm3的比例呈上升趋势(χ2趋势=4.250,P<0.001)。首次CD4细胞检测与确证间隔时间≤14 d的有3 465例,占71.68%;>14~30 d的有740例,占15.31%;>30~90 d的有315例,占6.52%;>90~180 d的有135例,占2.79%;>180 d的有179例,占3.70%。2012—2021年首次CD4细胞检测与确证间隔时间≤14 d的比例呈上升趋势(χ2趋势=6.874,P<0.001)。多因素logistic回归分析结果显示,女性(OR=0.630,95%CI:0.529~0.751)、年龄≥20岁(OR:1.958~3.218,95%CI:1.216~5.412)、其他感染途径或不详(OR=1.785,95%CI:1.100~2.896)、医疗机构检测发现(OR=1.779,95%CI:1.497~2.114)是首次检测CD4细胞计数<200个/mm3的影响因素。结论 2012—2021年台州市新报告HIV/AIDS病例首次检测CD4细胞及时性逐年提升,有34.42%的病例CD4细胞计数<200个/mm3;性别、年龄、感染途径和样本来源是首次检测CD4细胞计数<200个/mm3的影响因素。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
王婷婷
汪剡灵
李桂霞
常玥
关键词 艾滋病CD4+T淋巴细胞检测及时性    
AbstractObjective To investigate the level and timeliness of CD4+T lymphocyte cell (CD4 cell) counts at first measurement among newly reported HIV/AIDS cases in Taizhou City, Zhejiang Province from 2012 to 2021, so as to provide insights into improving the management of HIV/AIDS cases. Methods Demographic data and first measurement of CD4 cell counts of newly reported HIV/AIDS cases in Taizhou City from 2012 to 2021 were collected from the HIV/AIDS Comprehensive Control System of Chinese Disease Prevention and Control Information System. The level and time of CD4 cell counts at first measurement were descriptively analyzed, and factors affecting CD4 cell counts at first measurement were identified using a multivariable logistic regression model. Results A total of 4 834 newly reported HIV/AIDS cases were recorded in Taizhou City from 2012 to 2021, including 3 889 men (80.45%), 2 005 cases at ages of 20 to 39 years (41.48%), and 2 130 farmers (44.06%). There were 1 664 cases (34.42%) with CD4 cell counts of <200/mm3 at first detection, 2 576 (53.29%) with CD4 cell counts of 200/mm3 to 499/mm3, and 594 (12.29%) with CD4 cell counts of ≥500/mm3. The proportion of CD4 cell counts of <200/mm3 showed a tendency towards a rise from 2012 to 2021 (χ2trend =4.250, P<0.001). There were 3 465 cases (71.68%) that had an interval of ≤14 days between the first detection of CD4 cell counts and confirmatory HIV test, 740 (15.31%) that had an interval of >14 to 30 days, 315 (6.52%) that had an interval of >30 to 90 days, 135 (2.79%) that had an interval of >90 to 180 days, and 179 (3.70%) that had an interval of >180 days. The proportion of an interval of ≤14 days appeared a tendency towards a rise from 2012 to 2021 (χ2trend=6.874, P<0.001). Multivariable logistic regression analysis identified women (OR=0.630, 95%CI: 0.529-0.751), age of ≥20 years (OR: 1.958 to 3.218, 95%CI: 1.216-5.412), other or unknown routes of HIV infection (OR=1.785, 95%CI: 1.100-2.896), and identification by medical institutions (OR=1.779, 95%CI: 1.497-2.114) as factors affecting CD4 cell counts of <200/mm3 at first measurement. Conclusions The timely detection of CD4 cell counts at first measurement gradually increased with year among newly reported HIV/AIDS cases in Taizhou City from 2012 to 2021; however, there were still 34.42% of cases with CD4 cell counts of <200/mm3. Gender, age, route of HIV infection, and sample source were factors affecting CD4 cell counts of <200/mm3 at first measurement.
Key wordsAIDS    CD4+T lymphocyte cell    timeliness of detection
收稿日期: 2023-02-08      修回日期: 2023-05-21      出版日期: 2023-07-10
中图分类号:  R512.91  
通信作者: 常玥,E-mail:yuer1840@126.com   
作者简介: 王婷婷,硕士,医师,主要从事艾滋病、性病防制工作
引用本文:   
王婷婷, 汪剡灵, 李桂霞, 常玥. 2012—2021年台州市新报告HIV/AIDS病例首次CD4+T淋巴细胞检测结果分析[J]. 预防医学, 2023, 35(7): 578-582.
WANG Tingting, WANG Shanling, LI Guixia, CHANG Yue. Analysis of the first measurement of CD4+T lymphocyte cell counts of newly reported HIV/AIDS cases in Taizhou City from 2012 to 2021. Preventive Medicine, 2023, 35(7): 578-582.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.07.006      或      http://www.zjyfyxzz.com/CN/Y2023/V35/I7/578
[1] 傅天颖,吴昊澄,鲁琴宝,等.2021年浙江省法定传染病疫情分析[J].预防医学,2022,34(8):842-847.
[2] 何纳. 中国艾滋病流行病学研究新进展[J].中华疾病控制杂志,2021,25(12):1365-1368,1480.
[3] DOUEK D C,BRENCHLEY J M,BETTS M R,et al.HIV preferentially infects HIV-specific CD4+T cells[J].Nature,2002,417(6884):95-98.
[4] 中国疾病预防控制中心.艾滋病病毒感染者随访工作指南(2016年版)[S/OL].[2023-05-21].https://max.book118.com/html/2019/0524/7123153162002026.shtm.
[5] 中华人民共和国国家卫生健康委员会.艾滋病和艾滋病病毒感染诊断:WS 293—2019[S/OL].[2023-05-21].http://www.nhc.gov.cn/wjw/s9491/201905/6430aa653728439c901a7340796e4723/files/84dffca4fb2c4293abb6be4d5353f924.pdf.
[6] 孙敏,张冉,罗叶,等.2 119例HIV/AIDS病例首次CD4+T淋巴细胞检测结果及影响因素分析[J].国际检验医学杂志,2022,43(4):479-484.
[7] 朱正平,吴苏姝,刘黎,等.南京市2014—2018年新报告HIV/AIDS病例特征和首次CD4+T淋巴细胞检测情况分析[J].中国艾滋病性病,2020,26(1):8-12.
[8] ERDINC F S,DOKUZOGUZ B,UNAL S,et al.Temporal trends in the epidemiology of HIV in Turkey[J].Curr HIV Res,2020,18(4):258-266.
[9] 吕鑫,朱益民,周晓红,等.2014—2019年下城区新报告HIV/AIDS病例首次CD4+T淋巴细胞检测结果及影响因素分析[J].预防医学,2020,32(11):1134-1137.
[10] 金茜,叶振淼,赵丽娜,等.2015年—2020年温州市新报告HIV/AIDS病例首次CD4+T淋巴细胞检测结果分析[J].中国卫生检验杂志,2022,32(4):457-460.
[11] 韩晶,汤后林,毛宇嵘.2012—2016年新报告HIV感染者首次CD4+T淋巴细胞检测情况分析[J].中国艾滋病性病,2018,24(5):461-465.
[12] GOVENDER S,OTWOMBE K,ESSIEN T,et al.CD4 counts and viral loads of newly diagnosed HIV-infected individuals:implications for treatment as prevention[J/OL].PLoS One,2014,9(3)[2023-05-21].https://doi.org/10.1371/journal.pone.0090754.
[13] 吕红,师亚男,郭斌,等.承德市2013—2019年新发现HIV/AIDS病例首次CD4+T淋巴细胞检测情况分析[J].中国皮肤性病学杂志,2020,34(9):1039-1043.
[14] 张之,邱涛,孙承青,等.2 175例新发现HIV感染者治疗前CD4+T细胞计数分析[J].安徽医科大学学报,2022,57(5):827-831.
[15] BAKER J V,PENG G,RAPKIN J,et al.Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases[J].J Acquir Immune Defic Syndr,2008,48(5):541-546.
[16] 黄琳,陈敏敏,李钰,等.惠州市自愿咨询检测与医务人员主动提供检测咨询发现艾滋病患者对比分析[J].预防医学情报杂志,2017,33(10):977-980.
[1] 俞素芬, 蒋青林, 戴杰. 2012—2021年吴兴区新报告HIV/AIDS病例晚发现及影响因素分析[J]. 预防医学, 2023, 35(9): 796-799.
[2] 郑伟, 张世勇, 杨纶砥, 熊华利. 基于年龄-时期-队列模型的1990—2019年我国艾滋病发病率趋势分析[J]. 预防医学, 2023, 35(8): 665-668,681.
[3] 姜海波, 洪航, 周健, 李继革, 史宏博, 谭诗文, 褚堃, 张丹丹. 宁波市HIV/AIDS病例新型毒品使用情况调查[J]. 预防医学, 2023, 35(6): 470-474.
[4] 柏建芸, 赵芳凝, 候金余, 郭燕, 郑敏娜, 李龙, 于茂河. 2005—2021年天津市医疗机构HIV/AIDS检测发现情况分析[J]. 预防医学, 2023, 35(6): 475-479.
[5] 徐亚华, 吴斌. 兰溪市120例HIV抗体筛查阳性样本确证结果分析[J]. 预防医学, 2023, 35(6): 538-540.
[6] 蔺茂文, 刘锐, 张凡, 李舒超, 刘建昭, 豆智慧, 孙春. 1996—2021年荆州市HIV/AIDS病例1年死亡分析[J]. 预防医学, 2023, 35(5): 396-400.
[7] 景正伟, 宁艳, 常文辉, 周超, 任强, 董丽芳, 贾华, 许诗瑶, 王志锋. 高校MSM人群HIV感染学生生存质量分析[J]. 预防医学, 2023, 35(4): 291-294.
[8] 许太彬, 程春荣, 段江洋, 兰培利, 段欣洋. 郑州市50岁及以上HIV/AIDS病例流行特征[J]. 预防医学, 2023, 35(4): 323-326.
[9] 陈银炜, 周洋, 刘珍, 张晓辉. 流动人口HIV感染孕产妇健康综合评价指标体系研究[J]. 预防医学, 2023, 35(3): 210-214.
[10] 蒋均, 陈军仙, 楼莲娟, 朱碧香, 查琏琦, 阮建军. 义乌市2016—2020年报告HIV/AIDS病例流动特征分析[J]. 预防医学, 2023, 35(1): 21-26.
[11] 张鹤美, 高四海, 陈向阳, 叶振淼, 李君, 赵丽娜, 苏德华, 胡文雪, 赖江宜, 陈婉君. 2006—2020年温州市新报告50岁及以上HIV/AIDS病例时空特征分析[J]. 预防医学, 2022, 34(5): 483-486.
[12] 张丽, 姚英, 胡锦峰, 潘忠廉. 上城区艾滋病自愿咨询检测门诊求询者特征及HIV感染情况分析[J]. 预防医学, 2022, 34(2): 161-165.
[13] 何丁玲, 冯世平, 赵霞, 郭利华, 吕春容, 李虹霞, 郭慧, 黄蕾. 艾滋病住院患者焦虑和抑郁情况调查[J]. 预防医学, 2022, 34(2): 166-170,175.
[14] 梁若枫, 周黎, 陈金花, 韩俊. 杭州市某高校大学生艾滋病防治知识、态度、行为调查[J]. 预防医学, 2022, 34(2): 208-212.
[15] 陈晓燕, 俞晓明, 刘淑文, 吴文杰, 张均和, 陈圆静. 舟山市艾滋病健康教育试点高校学生艾滋病相关知识、态度、行为调查[J]. 预防医学, 2022, 34(2): 203-207.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed